Future Perspectives From a Case Report of Transcranial Magnetic Stimulation, Cognitive Behavioral Therapy, and Psychopharmacological Treatment for Post-traumatic Stress Disorder by Seybert, Carolina et al.
OPINION
published: 13 September 2021
doi: 10.3389/fpsyg.2021.728130
Frontiers in Psychology | www.frontiersin.org 1 September 2021 | Volume 12 | Article 728130
Edited by:
Antje Dr. Buettner-Teleaga,









This article was submitted to
Psychology for Clinical Settings,
a section of the journal
Frontiers in Psychology
Received: 20 June 2021
Accepted: 18 August 2021
Published: 13 September 2021
Citation:
Seybert C, Cotovio G, Grácio J and
Oliveira-Maia AJ (2021) Future
Perspectives From a Case Report of
Transcranial Magnetic Stimulation,





Future Perspectives From a Case




for Post-traumatic Stress Disorder
Carolina Seybert 1, Gonçalo Cotovio 1,2,3, Jaime Grácio 1,2 and Albino J. Oliveira-Maia 1,2*
1Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal, 2NOVA Medical
School, NMS, Universidade Nova de Lisboa, Lisbon, Portugal, 3Department of Psychiatry and Mental Health, Centro
Hospitalar de Lisboa Ocidental, Lisbon, Portugal
Keywords: posttraumatic stress disorder, combined treatment, psychotherapy, psychopharmacology, treatment,
transcranial magnetic stimulation
INTRODUCTION
Post-traumatic Stress Disorder (PTSD) is a stress-related condition that occurs after experiencing
or witnessing a traumatic event, such as a threat to physical integrity, or a potentially
life-endangering situation, including a serious car accident, physical and/or psychological abuse,
or sexual assault. It is a severe and debilitating psychiatric disorder, often resulting in professional
disability, weakened relationships, decreased cognitive and psychosocial functioning, and frequent
use of health care services due to physical conditions and mental comorbidities, such as substance
abuse, major depressive disorder (MDD) or even suicide. The occurrence of PTSD throughout life
varies between 0.56 and 6.67% among the European population (Burri and Maercker, 2014), with
concerns of increasing rates due to the COVID-19 pandemic (Salehi et al., 2021). In Portugal, where
the authors are based, PTSD was found to be one the most disabling mental health conditions,
with patients reporting disability with six times higher likelihood than study controls (Antunes
et al., 2018). Hence, there is an urge for effective and fast acting treatments in this condition. One
potential successful strategy, which has become a common practice in mental health, particularly
when the outcomes of first-line treatments are unsatisfactory due to inefficacy or debilitating
side-effects, is combining different therapeutic modalities.
Currently available treatment options, such as psychopharmacology (Brady et al., 2000;
Marshall et al., 2001) and/or psychotherapy (Monson and Shnaider, 2014; Forbes, 2020), are
frequently insufficient (Hoskins et al., 2015), and innovative therapeutic strategies are necessary.
In similarly debilitating disorders, such as MDD, options for therapeutic neuromodulation, such as
Transcranial Magnetic Stimulation (TMS), are clinically effective (Berlim et al., 2013; Gaynes et al.,
2014;Mutz et al., 2018). In fact, following approval by the US Food andDrugAdministration (FDA)
in 2008, TMS has been highly successful in alleviating symptoms of treatment resistant MDD and,
in 2015, the UK’s National Institute for Health and Care Excellence also recommended the use of
TMS in MDD treatment. TMS is a non-invasive and safe neuromodulation technique, resulting
from generation of an electromagnetic field by a coil which, when applied over the skull, elicits a
focal electric current in the underlying cortical tissue. Such stimulation, when applied repetitively
(repetitive TMS; rTMS), has more long-lasting modulatory effects on the activity of the underlying
cortical nervous tissue (Radhu et al., 2016).
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Over the last years, evidence has accumulated that rTMS may
be effective in the treatment of PTSD (Cohen et al., 2004; Boggio
et al., 2010; Watts et al., 2012; Ahmadizadeh and Rezaei, 2018),
with guidelines prepared by a large group of European experts
suggesting that it is probably effective (Lefaucheur et al., 2020),
and supporting off-label use in selected patients. In one sham-
controlled study (Ahmadizadeh and Rezaei, 2018), 58 patients
with PTSD were randomized to receive 20 Hz-rTMS over the
right dorsolateral prefrontal cortex (DLPFC; n= 19), or over the
right and left DLPFC (n= 19), or sham stimulation (n= 20), for
10 sessions over 4 weeks. The parameters of stimulation for the
active rTMS arms consisted in 2,400 pulses/session over the right
DLPFC or 1,200 pulses over the right DLPFC followed by 1,200
pulses over the left DLPFC, performed at 100% of the resting
motor threshold (RMT). A larger proportion of responders,
as assessed by reduction of total score in the PTSD checklist
military version, was found among the real stimulation groups,
with no significant difference between unilateral and bilateral
stimulation, when compared to the sham group (41.2 and 62.5
vs. 0% of responders, respectively).
Importantly, other studies have shownmoderate to significant
improvements when using a combination of rTMSwith cognitive
and behavioral interventions (Osuch et al., 2009; Isserles et al.,
2013; Kozel et al., 2018). These studies combined different
TMS treatment protocols with various interventions such as
imaginal exposure before rTMS sessions (Osuch et al., 2009),
brief script-driven exposure during deep TMS sessions (Isserles
et al., 2013) and cognitive processing therapy (CPT) after rTMS
sessions (Kozel et al., 2018). This is, at least in part, consistent
with evidence for the therapeutic effects of psychotherapy
assisted by 3,4-methylenedioxymethamphetamine (MDMA) to
treat PTSD (Mitchell et al., 2021), and the use of brief symptom
provocation prior to rTMS for obsessive-compulsive disorder,
in accordance with the protocol cleared by the FDA (Carmi
et al., 2019). Positive findings regarding the combination of
rTMS and psychotherapy have also been described for other
disorders, namely MDD. For example, in a large naturalistic
study of 196 patients treated with at least 10 sessions of rTMS
and simultaneous cognitive therapy for MDD, the authors
found 66 and 56% response and remission rates, respectively,
with sustained remission rates of 60% at 6 month follow up
(Donse et al., 2018). Nevertheless, little is known about the
neurobiological and psychological factors that might contribute
toward enhancement of treatment efficacy, with further research
necessary for a better understanding of such enhancement and
contributing factors.
At our center, rTMS is delivered mostly for depression,
but only rarely as monotherapy. In most cases, given that
it is delivered due to resistance to other treatments, rTMS
is applied in combination with other strategies, namely
psychopharmacological treatments, but also psychotherapy.
In fact, despite our current psychotherapeutic interventions
not being tailored for rTMS treatment, in several patients
we have observed a positive impact of rTMS on ongoing
psychotherapeutic work, possibly reflecting an interaction
between the two treatments. To illustrate the potential benefits of
this combined intervention in PTSD, here we will present the case
of a patient diagnosed with PTSD, with apparent benefit from the
combination of both treatment strategies.
CASE DESCRIPTION
The case is that of a 45-year-old woman that, 4 years before
coming to our center, had been involved in a severe car accident,
while driving. After this event she reported the beginning of
nightmares and daydreams involving the accident as well as
disabling avoidant behaviors, such as not leaving the house due
to fear of having another accident. She also reported frequent
panic attacks and loss of balance without any related medical
findings. She referred important relational difficulties, which
culminated in separating from her husband just 1 month after
the accident. Additionally, despite being highly functioning prior
to the accident, 2 years after she had lost her job and since then
had been incapable of resuming any working activity, due to her
mental symptoms as well as chronic back pain.
Treatment for her condition had been attempted by different
psychiatrists with several psychopharmacological treatments,
including sertraline, trazodone, venlafaxine and quetiapine, with
little or no relief. When first observed she was also taking
high doses of several benzodiazepines, and attending long-term
psychotherapy, as well as a pain-management program in a
group setting, all without success. Concerning past psychiatric
history, she had suffered a major depressive episode at ∼20
years old, when her grandmother passed away. This episode
was successfully treated with 2 years of psychopharmacological
treatment, and it had not recurred since. The patient did not
recall which specific agents were prescribed at that time. Apart
from dyslipidemia, no other medical conditions were reported.
In this clinical context, she was diagnosed with PTSD
and comorbid benzodiazepine use disorder. The current
psychopharmacological treatment was optimized with
fluoxetine, pregabalin, clorazepate dipotassium, and quetiapine.
Additionally, a new psychotherapeutic treatment was offered.
Due to her depressive symptoms and anxiety, the patient adhered
to this treatment with difficulty, attending a total of 11 cognitive-
behavioral psychotherapy (CBT) sessions over 8 months. While
it was possible to discontinue almost all benzodiazepines, after
8 months of treatment with optimized doses of fluoxetine
(60mg qid), clorazepate dipotassium (30mg qid), pregabalin
(250mg qid) and quetiapine (up to 150mg qid), little clinical
improvement was observed for PTSD symptoms, and alternative
treatment options were proposed. Specifically, the patient agreed
to, and signed informed consent for, off-label use of rTMS for
PTSD, as an augmentation strategy for ongoing medication
and psychotherapy.
rTMS TREATMENT
The protocol for off-label use of rTMS for PTSD was defined
according to data described in the evidence-based guidelines
for therapeutic use of rTMS (Lefaucheur et al., 2020). High
frequency (20Hz) rTMS, was performed daily, Monday through
Friday, in ∼30 min-long sessions, with 2,400 pulses (2 s on and
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TABLE 1 | Clinical outcomes for combined rTMS treatment.
Session BDI-II STAI-S PCL-5 CAPS-5
(% change) (% change) (% change) (% change)

















BDI-II, Beck Depression Inventory; STAI-S, State-Trait Anxiety Inventory State Subscale;
PCL-5, Posttraumatic Stress Disorder Checklist for DSM-5; CAPS-5, Clinician-
Administered PTSD Scale for DSM-5.
28 s off) delivered at 100% of the RMT over the right DLPFC,
across 6 weeks (i.e., an acute treatment cycle of 30 sessions).
We used the MagVenture Coil Cool-B65, targeting the DLPFC
using the “5.5 cm rule” localization method (McClintock et al.,
2018). Following the acute treatment, 6 continuation sessions,
performed every 2 weeks with the same stimulation protocol,
were offered. During acute and continuations rTMS, the patient
attended a total of 5 CBT sessions in 5 months. At the same
time, the psychopharmacological treatment remained stable for
fluoxetine (60mg qid) and quetiapine SR (150mg qid). The
dose of pregabalin was gradually raised to 400mg qid while
clorazepate dipotassium (30mg qid) was terminated.
In addition to the clinical evaluations by the treating
clinicians, symptoms were assessed at the beginning, during
and at the end of the rTMS treatment as presented in Table 1.
The Beck Depression Inventory (BDI-II) (Beck et al., 1996;
Campos and Gonçalves, 2011) was used to assess the severity of
depression at baseline, weekly and at the end of the acute and
continuation treatment cycles. The State Trait Anxiety Inventory
(STAI) (Spielberger et al., 1983; Silva and Campos, 1998) was
collected at the same time points in order to measure self-
reported anxiety symptoms that commonly co-occur with PTSD
(Brady et al., 2000). In order to assess PTSD symptomatology,
the self-rated PTSD Checklist for DSM-5 (PCL-5) (Blevins et al.,
2015; Carvalho et al., 2020), was used. Finally, at baseline and
at the end of acute and continuation treatment cycles, PTSD
symptoms were also assessed using Clinician-Administered
PTSD Scale for DSM-5 (CAPS-5) (Weathers et al., 2018; Oliveira-
Watanabe et al., 2019). After 4 weeks of the acute rTMS
cycle, depressive symptom severity reduced 50% (from a BDI-
II total score of 32–16) and the CAPS-5 score reduced 38%
(from a total score of 47–29). A smaller reduction in symptoms
severity was observed on self-reported anxiety (−11.6%; STAI-
State) and PTSD symptoms (−14.5%; PCL-5). Nevertheless,
an impressive symptom reduction continued until the end of
rTMS continuation sessions, especially on the CAPS-5 score, that
reduced almost 60% at the end of rTMS (Table 1).
In the years after completing rTMS treatment, the patient
continued attending psychotherapy sessions and psychiatric
appointments, albeit less frequently. Contrary to prior to rTMS,
throughout the post-rTMS CBT sessions, she became able to
elaborate on cognitive restructuring, as well as conduct breathing
and relaxation techniques. Before rTMS treatment, she was
unable to engage in any exposure techniques implemented by
her cognitive-behavioral psychotherapist due to severe sadness,
anguish and unbearable anxiety. For the first time, she was
generalizing the use of behavioral and cognitive control strategies
between sessions. Currently, the patient reports stable remission
of her symptoms, as well as significant recovery of functionality.
DISCUSSION
In the present case, the addition of an off-label rTMS protocol
for PTSD to ongoing treatments was successful. While the
psychopharmacological and CBT treatments offered previously
had produced unsatisfactory results, after rTMS the patient
rapidly showed a decrease in symptom severity. While this
may simply result from the benefit of rTMS per se, we believe
this case report may reflect the potential impact of combining
rTMS with psychotherapy. In this case, the rapid symptomatic
improvement of both depressive and PTSD symptoms, once
rTMS was offered, helped the patient to finally engage in
psychotherapeutic work that was being offered in psychotherapy.
Moreover, the well-known positive effects of rTMS on cognitive
functioning (Bajbouj and Padberg, 2014) might have contributed
to her deeper engagement in psychotherapy sessions. In fact,
she became more prone to working with her psychotherapist
and participated in techniques that had been emotionally
unbearable and of limited use before starting rTMS. On the other
hand, the already established psychotherapeutic relationship
(Horvath et al., 2011) might have potentiated the expectation
regarding TMS, prompting patient commitment to daily TMS
treatment sessions, a critical moderator for clinically effective
rTMS neurobiological effect (Galletly et al., 2012; Modirrousta
et al., 2018). Often, for patients with PTSD, daily outgoings for
TMS treatment might be challenging. This combined setting
may have contributed to treatment adherence, since no rTMS
session was missed for the ∼5 months duration of rTMS acute
and continuation treatments. Importantly, treatment adherence
and expectations are known to be important contributors for
better outcomes in various treatment modalities (Horwitz, 1993;
Constantino et al., 2021).
Concerning the current evidence, well-illustrated by this case
report, we believe that combining neuromodulation techniques
with psychotherapy, as well as psychopharmacologic agents,
is a promising approach in treatment of neuropsychiatric
disorders, particularly in challenging or treatment-refractory
cases. Nevertheless, the augmenting effect of TMS on
psychotherapeutic work should be further explored, using
carefully designed randomized control trials. Additionally,
we believe that the neurobiological mechanisms supporting
the clinical efficacy of combining these treatment modalities
should also be clarified. Such path will certainly allow improving
psychotherapy design as well as that of rTMS protocols.
Ultimately, increasing the knowledge about combined TMS,
psychopharmacological and psychotherapeutic strategies
will help develop individualized treatments, increasing the
likelihood of symptom remission while improving quality
of life.
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